Key Points
- Insider sold: Esther Rajavelu sold 25,240 Spero (NASDAQ:SPRO) shares on May 4 at an average $2.51 for ~$63,352, reducing her stake by 2.49% to 986,851 shares; the sale was to cover tax withholding on vested equity and follows a Feb. 6 sale of 87,917 shares.
- Earnings beat: Spero reported $0.53 EPS versus a -$0.20 estimate and revenue of $41.3M versus $26M, while the company’s market cap is about $146M and the stock trades near its 50‑day average (~$2.51).
- Mixed sentiment and institutions: Analyst coverage is mixed with an average "Reduce" rating, while institutional investors hold ~25.6% of shares and GSK established a new ~ $21.4M stake in Q4.
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 25,240 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $2.51, for a total value of $63,352.40. Following the transaction, the insider owned 986,851 shares of the company's stock, valued at $2,476,996.01. This represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Esther Rajavelu also recently made the following trade(s):
- On Friday, February 6th, Esther Rajavelu sold 87,917 shares of Spero Therapeutics stock. The shares were sold at an average price of $2.36, for a total value of $207,484.12.
Spero Therapeutics Stock Performance
NASDAQ SPRO opened at $2.53 on Thursday. The company has a market capitalization of $146.49 million, a P/E ratio of 21.09 and a beta of 1.43. Spero Therapeutics, Inc. has a one year low of $0.57 and a one year high of $3.22. The stock has a 50 day moving average price of $2.51 and a 200-day moving average price of $2.41.
Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its earnings results on Thursday, March 26th. The company reported $0.53 EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.73. The firm had revenue of $41.30 million during the quarter, compared to the consensus estimate of $26.00 million. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%.
Analysts Set New Price Targets
SPRO has been the subject of a number of research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Spero Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen upgraded Spero Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Sunday, March 29th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Reduce".
Read Our Latest Stock Report on Spero Therapeutics
Institutional Trading of Spero Therapeutics
A number of institutional investors have recently bought and sold shares of the stock. GSK plc bought a new stake in Spero Therapeutics in the fourth quarter worth $21,414,000. Vanguard Group Inc. lifted its position in Spero Therapeutics by 2.0% in the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company's stock worth $3,741,000 after buying an additional 39,474 shares during the last quarter. State Street Corp lifted its position in Spero Therapeutics by 10.1% in the fourth quarter. State Street Corp now owns 210,151 shares of the company's stock worth $490,000 after buying an additional 19,200 shares during the last quarter. Ionic Capital Management LLC lifted its position in Spero Therapeutics by 39.2% in the third quarter. Ionic Capital Management LLC now owns 208,725 shares of the company's stock worth $392,000 after buying an additional 58,725 shares during the last quarter. Finally, Intrepid Family Office LLC lifted its position in Spero Therapeutics by 50.0% in the fourth quarter. Intrepid Family Office LLC now owns 165,000 shares of the company's stock worth $384,000 after buying an additional 55,000 shares during the last quarter. 25.60% of the stock is currently owned by institutional investors.
Spero Therapeutics Company Profile
(
Get Free Report)
Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.
The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
